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Intrarenal arterial stiffness is increased in systemic
sclerosis patients with antiribonucleic acid poly-
merase III antibodies
Rheumatology key message
. Intrarenal arterial stiffness is increased in SSc pa-
tients with anti-RNA polymerase III antibodies.
SIR, SSc is an autoimmune disease characterized by
endothelial dysfunction and skin and internal organs fibro-
sis [1]. The subclinical renal impairment (50% of patients)
is characterized by an increase of Doppler indices of
intrarenal arterial stiffness [24]. Recent data demonstrate
strong associations between anti-RNA polymerase III anti-
bodies and scleroderma renal crisis (SRC). SRC and major
vascular complications usually develop in the first years of
the disease [2]. The aim of this study was to evaluate the
Doppler indices of intrarenal arterial stiffness in SSc pa-
tients with anti-RNA polymerase III antibodies.
We enrolled 33 consecutive SSc patients [28 female
and 5 male; mean age 48.4 years (S.D. 11.2)] fulfilling the
ACR/EULAR criteria: 11 with anti-RNA polymerase anti-
bodies (ARAs), 11 with anti-topoisomerase I antibodies
(ATAs) and 11 with ACAs [5]. Patients with double positiv-
ity for antibodies were excluded. The mean disease dur-
ation was 8 years (S.D. 5.4). Sixteen patients had lcSSc
and 18 had dcSSc.
Patients with SRC, obstructive and vascular kidney dis-
ease, abnormal urinary sediment, glomerulonephritis, ele-
vated serum creatinine concentration, uncontrolled
systemic hypertension, hyperlipidaemia, cardiac and hep-
atic failure, diabetes, cerebrovascular and peripheral vas-
cular diseases, coagulopathy, smokers and pregnant or
breastfeeding women were excluded.
All SSc patients underwent treatment with nifedipine
(30 mg/day), 20 patients were receiving prostanoid ther-
apy and 13 received Bosentan. Thirty healthy controls
[25 female and 5 male, mean age 47 years (S.D. 11.5)]
were enrolled. The subjects’ written consent was obtained
according to the Declaration of Helsinki and the study was
approved by the Sapienza ethics committee.
SSc patients and healthy controls underwent Doppler
US after acclimation (15 min) in a temperature-controlled
room [22C (S.D. 0.4)]. Renal Doppler US was performed
using a Toshiba Aplio Ultrasound System SSA-790
equipped with a convex 3.5 MHz probe as in our previous
studies [3, 4]. Nailfold videocapillaroscopy was performed
with a videocapillaroscope equipped with a 500 optical
probe according to Cutolo et al. [6]. Analysis for ANAs was
performed by indirect immunofluorescence using HEp-2
cells (Euroimmun, Lubeck, Germany). ATA and ARA con-
centrations were measured using QUANTA Lite Scl70
ELISA (Inova Diagnostics, San Diego, CA, USA). All the
results were expressed as mean (S.D.) or median (range).
Group comparisons were made by Student’s unpaired
two-tailed t-test or KruskalWallis test. Pearson or
Spearman correlation coefficients (r) were used as appro-
priate. The chi-square test or Fisher’s exact test was used
to compare categorical variables. P-values <0.05 were
considered significant.
The pulsatile index (PI) [1.26 (0.15) vs 1.04 (0.16)], re-
sistive index (RI) [0.66 (0.04) vs 0.50 (0.05)] and sys-
tolic:diastolic (S/D) ratio [3.04 (0.52) vs 2.07 (0.21)] were
significantly higher (P< 0.0001) in SSc patients than in
healthy controls. In SSc patients, no statistical correl-
ations were observed between Doppler indices and age
and subset of disease. Doppler indices were significantly
higher in SSc patients with ARAs than in SSc patients with
ACAs or ATAs. The PI was higher (P< 0.05) in SSc pa-
tients with ARAs [1.37 (1.121.75)] then in SSc patients
with ATAs [1.21 (1.041.38)] and ACAs [1.22 (1.061.42)].
The RI was higher (P< 0.01) in SSc patients with ARAs
[0.69 (0.640.80)] than SSc patients with ATAs [0.64
(0.610.67)] and ACAs [0.65 (0.600.69)]. The S/D ratio
was higher (P< 0.05) in SSc patients with ARAs [3.32
(2.725.11)] then in SSc patients with ATAs [2.79
(2.523.29)] and ACAs [2.85 (2.433.41)]. No significant
differences in Doppler indices were observed between
SSc patients with ATAs and ACAs (Fig. 1).
Twelve patients had an early capillaroscopic pattern, 9
patients had an active pattern and 12 patients had a late
pattern. The median values of PI, RI and S/D ratio in the
three capillaroscopic groups were, respectively, 1.15
(1.041.29), 1.24 (1.091.42) and 1.36 (1.161.75); 0.64
(0.600.69), 0.64 (0.660.68) and 0.68 (0.640.80); and
2.77 (2.503.29), 3.01 (2.743.41) and 3.15 (2.435.11).
The PI (P< 0.01), RI (P< 0.01) and S/D ratio (P< 0.05)
significantly increased with the progression of capillaro-
scopic damage.
Fifteen SSc patients had a history of digital ulcers (DUs).
The PI [1.26 (1.091.75) vs 1.19 (1.041.42), P< 0.05], RI
[0.67 (0.650.80) vs 0.64 (0.600.69), P< 0.001] and S/D
ratio [3.06 (2.435.11) vs 2.78 (2.503.41), P< 0.01] were
significantly higher in SSC patients with a history of DUs
than in SSc patients without a history of DUs.
Doppler indices of intrarenal arterial stiffness were
higher in SSc patients than healthy controls and they sig-
nificantly increased with the progression of digital micro-
vascular damage. These Doppler indices showed a
negative correlation with glomerular filtration rate and
they are a reliable marker of new DU occurrence [3, 4].
For the first time, we demonstrated that in SSc patients
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with ARAs the Doppler indices of intrarenal arterial stiff-
ness are higher than in SSc patients with ATAs and ACAs.
Renal vasculopathy seems to be the main pathogenic
mechanism of all SSc renal manifestations, including
SRC. Although ARAs were immunologic predictors of de-
veloping SRC, we assume that they have a pathogenic
role in subclinical renal vascular damage [7, 8].
We can hypothesize that in SSc patients with ARAs
and elevated Doppler indices of intrarenal arterial stiff-
ness there is a high risk of developing renal vascular
complications.
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The potential overlapping populations for treat-
ment with belimumab and rituximab using current
NHS England and National Institute for Health and
Care Excellence Guidelines in England and Wales
Rheumatology key message
. Of UK SLE patients with disease requiring biologic
therapy, 13% are eligible for belimumab.
SIR, Belimumab, an anti-B lymphocyte stimulator mAb, has
proven efficacy for the treatment of SLE [1, 2]. The European
licence is based on post hoc analysis of randomized trials
showing that predictors of better response include elevated
antibodies to dsDNA, low complement and higher Safety of
Estrogens in Lupus Erythematosus National Assessment -
Systemic Lupus Erythematosus Disease Activity Index
(SELENA-SLEDAI) scores [3, 4]. Patients with severe active
LN or CNS lupus were excluded from these trials and do not
form part of the patient population assessed as part of the
marketing authorization [1, 2]. In June 2016, The National
Institute for Health and Care Excellence recommended the
use of belimumab as add-on therapy for patients with active
auto-antibody-positive SLE, who have serological activity
(defined as positive anti-dsDNA and low complement) and a
SELENA-SLEDAI score510, despite standard treatment [5].
Since 2010, patients commencing biologic therapy for
SLE in the UK have been registered in the BILAG-BR, the
initial results of which are presented in a paper currently
under review (McCarthy et al., manuscript under review).
We sought to investigate the number of patients and the
clinical characteristics of patients treated with a biologic in
the BILAG-BR who would potentially have been eligible
for belimumab using this guidance [5].
Of the 270 patients registered for biologic use to
November 2015, 82 (33%) had evidence of both low com-
plement and elevated anti-dsDNA antibodies at enrol-
ment. Of these, 46 (56.1%) patients had a BILAG A in
the renal (n = 29) or neuropsychiatric system (n = 17),
making them ineligible for therapy. An additional four
(4.9%) had a SLEDAI score<10. Thus, from 2010 to
2015, 32 patients (13%) enrolled in the BILAG-BR would
have been eligible for belimumab.
Amongst these 32 patients, the BILAG mucocutaneous
(MUC) and musculoskeletal (MSK) systems had the most
frequent A (MSK = 7, MUC = 6) and B scores (MSK = 11,
MUC = 8; Fig. 1). Seventeen (53%) patients had a history
of renal disease. The median [interquartile range (IQR)]
baseline SLEDAI was 12.5 (1215.75).
Regarding medication use, 28 (87.5%) and 27 (84.4%)
patients were on an anti-malarial or oral prednisolone, re-
spectively. The median (IQR) baseline prednisolone dose
was 15 mg (1020 mg). The median (IQR) number of prior
standard immunosupressant agents was 2 (13). MMF
was the most frequently prescribed therapy (n = 23), fol-
lowed by AZA (n = 15) and CYC (n = 11).
When we assessed response to Rituximab (RTX) in this
cohort who would now be eligible for belimumab, the
median (IQR) SLEDAI improved from 12.5 (1215.75) at
baseline to 4 (08) at 6 months (P< 0.0001). The total
number of BILAG A scores reduced from 16 to 2 and B
scores from 33 to 9. A corresponding reduction in CS
dose was also noted from 15 mg (1020 mg) to 6 mg
(510 mg) at 6 months (P< 0.001).
Improved access to biologic therapies will enhance
physicians’ ability to control disease activity while facilitat-
ing CS tapering and preventing damage [6]. Given that the
response rate to most biologic therapies in SLE is 50%,
the addition of belimumab to UK physicians’ armament-
arium is to be welcomed, especially for those patients
who have not responded to conventional therapy. Our
data will help inform clinicians and planners about the
expected rates of usage and the clinical characteristics
of patients requiring belimumab in the UK. MUC and
MSK were the systems most likely to have active disease
requiring belimumab. A history of renal involvement was,
however, noted in 50% of cases, emphasizing that pre-
vious renal involvement does not exclude patients from
belimumab; indeed, both the Belimumab in Subjects
With Systemic Lupus Erythematosus (BLISS)-52 and 76
trials included patients with active renal disease, and a
post hoc analysis suggested favourable renal outcomes
in this population [7]. Our data also suggest that RTX re-
mains a realistic therapeutic option for patients who fail to
respond to belimumab.
FIG. 1 BILAG-2004 organ systems with active disease in
SLE patients eligible for belimumab
Number of individual patients scoring either an A or B on
BILAG-2004 scoring system across the systems
assessed.
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